Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	2 shs
INFI Infinity Pharmaceuticals		$0.07	$0.01 ▼ $0.01	$726K	1.63	2.58 million shs	2.48 million shs
MBIO Mustang Bio	$2.18 -6.0%	$1.48	$0.89 ▼ $24.00	$10.16M	2.16	1.62 million shs	373,533 shs
TFFP TFF Pharmaceuticals	$0.07	$0.06	$0.06 ▼ $3.23	N/A	0.98	1.03 million shs	N/A
VYNE VYNE Therapeutics	$1.16 -3.3%	$1.16	$0.85 ▼ $4.30	$18.25M	1.78	231,238 shs	753,325 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
INFI Infinity Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MBIO Mustang Bio	+4.98%	-13.43%	+127.45%	+74.44%	-87.36%
TFFP TFF Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-96.64%
VYNE VYNE Therapeutics	-4.76%	-13.04%	+30.63%	-35.14%	-46.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INFI Infinity Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	0.9261 of 5 stars	0.0	5.0	0.0	0.0	2.1	0.0	0.6
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	2.9445 of 5 stars	3.5	3.0	0.0	0.0	3.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	0.00	N/A	N/A	N/A
INFI Infinity Pharmaceuticals	0.00	N/A	N/A	N/A
MBIO Mustang Bio	0.00	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	0.00	N/A	N/A	N/A
VYNE VYNE Therapeutics	3.00	Buy	$6.25	438.79% Upside

Current Analyst Ratings Breakdown

Latest INFI, MBIO, VYNE, ALPN, and TFFP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/25/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.75 ➝ $4.50

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
INFI Infinity Pharmaceuticals	$2.59M	0.00	N/A	N/A	($0.21) per share	0.00
MBIO Mustang Bio	N/A	N/A	N/A	N/A	($2.11) per share	N/A
TFFP TFF Pharmaceuticals	$730K	0.40	N/A	N/A	$4.04 per share	0.02
VYNE VYNE Therapeutics	$500K	35.29	N/A	N/A	$3.53 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
INFI Infinity Pharmaceuticals	-$44.37M	-$0.46	N/A	N/A	N/A	-1,593.93%	N/A	-113.02%	N/A
MBIO Mustang Bio	-$15.75M	-$78.00	0.00	N/A	N/A	N/A	N/A	-80.79%	8/12/2025 (Estimated)
TFFP TFF Pharmaceuticals	-$21.24M	-$6.44	0.00	∞	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	-$39.83M	-$0.99	0.00	N/A	N/A	-6,974.55%	-71.89%	-58.94%	8/13/2025 (Estimated)

Latest INFI, MBIO, VYNE, ALPN, and TFFP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	VYNE VYNE Therapeutics	-$0.24	N/A	N/A	N/A	$0.15 million	N/A
5/14/2025	Q1 2025	MBIO Mustang Bio	N/A	-$0.05	N/A	-$0.05	N/A	N/A
5/8/2025	Q1 2025	VYNE VYNE Therapeutics	-$0.29	-$0.20	+$0.09	-$0.20	$0.05 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
INFI Infinity Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
TFFP TFF Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
INFI Infinity Pharmaceuticals	N/A	1.65	1.65
MBIO Mustang Bio	N/A	1.34	1.34
TFFP TFF Pharmaceuticals	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	4.47	4.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
INFI Infinity Pharmaceuticals	22.14%
MBIO Mustang Bio	9.95%
TFFP TFF Pharmaceuticals	15.25%
VYNE VYNE Therapeutics	83.78%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
INFI Infinity Pharmaceuticals	9.81%
MBIO Mustang Bio	0.21%
TFFP TFF Pharmaceuticals	4.50%
VYNE VYNE Therapeutics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	Optionable
INFI Infinity Pharmaceuticals	30	90.76 million	81.86 million	Optionable
MBIO Mustang Bio	100	4.38 million	4.37 million	Not Optionable
TFFP TFF Pharmaceuticals	19	4.44 million	4.24 million	Optionable
VYNE VYNE Therapeutics	30	15.21 million	14.48 million	Not Optionable

INFI, MBIO, VYNE, ALPN, and TFFP Headlines

Recent News About These Companies

VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress

July 11, 2025 | insidermonkey.com

VYNE Therapeutics (NASDAQ:VYNE) Stock Price Down 9.5% - Should You Sell?

July 8, 2025 | americanbankingnews.com

Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor

July 2, 2025 | fiercebiotech.comF

VYNE Therapeutics Provides Update on VYN202 Program Following FDA Clinical Hold for Psoriasis Trial

July 2, 2025 | quiverquant.comQ

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

July 2, 2025 | globenewswire.com

VYNE Stock Touches 52-Week Low at $0.96 Amid Market Challenges

May 31, 2025 | investing.com

VYNE Therapeutics First Quarter 2025 Earnings: Beats Expectations

May 12, 2025 | finance.yahoo.com

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

VYNE Therapeutics' Psoriasis Drug Trial Halted By FDA Over Toxicity Concerns; Stock Down.

April 27, 2025 | nasdaq.com

VYNE Therapeutics Inc. Faces FDA Clinical Hold on VYN202 Phase 1b Trial for Plaque Psoriasis

April 27, 2025 | nasdaq.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)

April 26, 2025 | markets.businessinsider.com

VYNE Therapeutics Inc.: VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025 | finanznachrichten.de

VYNE shares tumble after FDA clinical hold on psoriasis drug study

April 25, 2025 | za.investing.com

Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis

April 25, 2025 | biospace.comB

FDA puts Vyne in a twist, slapping hold on psoriasis trial over testicular toxicity concerns

April 25, 2025 | fiercebiotech.comF

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

April 25, 2025 | benzinga.com

VYNE Therapeutics Provides Update on VYN202 Program

April 25, 2025 | globenewswire.com

Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

April 9, 2025 | finanznachrichten.de

Artiva Biotherapeutics Names New Chief Medical Officer

April 8, 2025 | marketwatch.com

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFI, MBIO, VYNE, ALPN, and TFFP Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Mustang Bio NASDAQ:MBIO

$2.18 -0.14 (-6.03%)

Closing price 04:00 PM Eastern

Extended Trading

$2.19 +0.01 (+0.69%)

As of 07:54 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

TFF Pharmaceuticals NASDAQ:TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

VYNE Therapeutics NASDAQ:VYNE

$1.16 -0.04 (-3.33%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.03 (+2.16%)

As of 06:24 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time